---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-118241"
form_type: "8-K"
ticker: "GPCR"
cik: "0001888886"
company_name: "Structure Therapeutics Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T04:07:37.528647+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Structure Therapeutics reports Q3 net loss of $23.9M, advances GSBR-1290 and forms Schrödinger collaboration

## Summary
- Phase 1b study of GSBR-1290 showed up to 4.9% placebo-adjusted weight loss; no AE-related discontinuations.
- Topline Phase 2a T2DM data expected December 2023; obesity cohort data H1 2024; global Phase 2b planned H2 2024.
- Completed $300M private placement in October 2023; cash $205.4M at Sept 30, extending runway through 2026.
- Collaboration with Schrödinger: up to $89M milestones plus low single-digit royalties on net sales.
- Net loss $23.9M for Q3 2023 vs $12.4M in Q3 2022; R&D expenses increased to $17.5M.

## SEC filing metadata
- accession: 0001104659-23-118241
- form_type: 8-K
- ticker: GPCR
- cik: 0001888886
- company_name: Structure Therapeutics Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1888886/000110465923118241/0001104659-23-118241-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1888886/000110465923118241/tm2329572d10_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-118241
- JSON: https://secwatch.observer/filing/0001104659-23-118241.json
- Plain text: https://secwatch.observer/filing/0001104659-23-118241.txt

## Key facts
- Earnings Releases
  Structure Therapeutics Inc. reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 14, 2023, the Company issued a press release providing a corporate update and announcing its financial results for the third quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1888886/000110465923118241/0001104659-23-118241-index.htm
- Material Agreements
  Structure Therapeutics Inc. entered into Aconcagua-Schrödinger Agreement with Schrödinger, Inc. valued at up to an aggregate of $89.0 million (effective 2023-11-07).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Schrödinger, Inc.
  - Value: up to an aggregate of $89.0 million
  - Effective: 2023-11-07
  source text: On November 7, 2023, Aconcagua Bio, Inc. (“Aconcagua”), a wholly-owned subsidiary of Structure Therapeutics Inc. (the “Company”), entered into a collaboration agreement (the “Aconcagua-Schrödinger Agreement”) with Schrödinger, Inc. (“Schrödinger”) to discover and develop novel, small molecule modulators of a specific target.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1888886/000110465923118241/0001104659-23-118241-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.